What Is Metronidazole Gel Used For?

Metronidazole gel is a topical antibiotic used primarily for two very different conditions: rosacea on the face and bacterial vaginosis in the vagina. In both cases, it delivers the drug directly where it is needed while keeping blood levels far lower than an oral pill would. The gel comes in concentrations of 0.75% and 1%, and the formulation matters less than you might expect, since studies have found overlapping results between the two strengths and between once-daily and twice-daily dosing. What makes metronidazole gel interesting is the range of problems it addresses and how its mechanism goes beyond simply killing bacteria.

How Metronidazole Gel Actually Works

Metronidazole is classified as an antibiotic, but when applied topically for rosacea, its benefit probably comes from more than germ-killing. Research suggests the drug also has anti-inflammatory and antioxidant properties. In lab studies, metronidazole appears to scavenge reactive oxygen species, the damaging molecules that contribute to the redness and tissue breakdown seen in rosacea and in aging skin generally.¹ That dual action helps explain why the gel works on rosacea even though rosacea is not a classic bacterial infection. It calms the inflamed skin rather than simply sterilizing it.

When used vaginally for bacterial vaginosis, the mechanism is more straightforward. Metronidazole targets anaerobic bacteria, the oxygen-avoiding organisms that overgrow during BV, including species such as Gardnerella vaginalis. The gel delivers high local concentrations of the drug against those bacteria while exposing the rest of the body to relatively little of it.

Rosacea and the Evidence Behind Topical Metronidazole

Rosacea is the condition most closely associated with metronidazole gel. A randomized trial in Japanese patients found that after 12 weeks of treatment with 0.75% metronidazole gel, about 72% achieved both a greater-than-50% drop in inflammatory lesions and a meaningful improvement in redness, compared with roughly 37% using a placebo gel.² Those numbers are typical of what trials show: the gel reliably cuts papules and pustules by more than half in the majority of patients.

The gel also helps keep rosacea from coming back. In a study where patients first cleared their flares using oral tetracycline plus metronidazole gel, those who continued applying the gel afterward relapsed at about half the rate of those who switched to a placebo. Only about 23% of the metronidazole group relapsed over six months, versus 42% on vehicle alone, and the metronidazole group had fewer papules and pustules at the end of the maintenance period.³ This makes the gel useful not just for treating active flares but for long-term management.

How It Stacks Up Against Other Rosacea Treatments

Metronidazole gel is effective, but it is not the top performer in every comparison. A head-to-head randomized trial pitting 0.75% metronidazole gel against 15% azelaic acid gel found that azelaic acid produced a significantly greater reduction in inflammatory lesions. Metronidazole brought the average lesion count down from about 19 to about 9, while azelaic acid brought a similar starting count down to roughly 5. Notably, metronidazole’s improvement plateaued after about eight weeks, whereas azelaic acid continued reducing lesions through week 15.⁴

Network meta-analyses, which pool data across many trials to rank treatments against one another, have generally placed ivermectin 1% cream and azelaic acid 20% ahead of metronidazole 0.75%, though all three outperform placebo by a wide margin. One such analysis ranked azelaic acid 20% highest, followed by ivermectin 1%, with metronidazole 0.75% in the middle of the pack.⁵ Another network meta-analysis found that ivermectin 1% cream applied once daily led to a significantly greater reduction in inflammatory lesions compared with metronidazole 0.75% cream applied twice daily at 12 weeks.⁶

None of this means metronidazole gel is a poor choice. It has decades of real-world use, a well-understood safety profile, and is available as a generic in many countries, making it cheaper than newer options. For mild-to-moderate papulopustular rosacea, especially when cost or tolerability matters, metronidazole remains a solid first-line option. But if you have tried it and your skin has plateaued at a level you are not happy with, the comparative data suggest ivermectin or azelaic acid might push you further.

Treating Bacterial Vaginosis

The vaginal version of metronidazole gel is a standard treatment for bacterial vaginosis, the most common vaginal infection in women of reproductive age. In a placebo-controlled trial, 87% of women treated with 0.75% metronidazole vaginal gel were free of BV at follow-up, compared with just 17% on placebo. The cure was accompanied by drops in the anaerobic bacteria responsible for symptoms like discharge and odor.⁷ That same trial noted, however, that about 15% of women who were initially cured developed recurrent BV within a month, a pattern that is common with all BV treatments and not unique to metronidazole.

A higher-concentration formulation, 1.3% metronidazole vaginal gel, has also been tested. In a large phase 3 trial, clinical cure at day 21 was about 37% for the metronidazole group versus 27% for placebo. Those numbers look lower than the earlier trial, but the cure definition was stricter and the follow-up was longer. At day 7, nearly half of treated participants already showed clinical cure, and the median time to symptom resolution was about 6 days.⁸ The takeaway is that the gel reliably clears BV in the short term, but recurrence remains a challenge regardless of the concentration used.

Why the Gel Route Matters for Systemic Exposure

One of the main reasons clinicians reach for metronidazole gel rather than pills is the difference in how much drug reaches the bloodstream. A pharmacokinetic study comparing the intravaginal gel to a standard 500 mg oral dose found that blood levels after vaginal application were only about 2% of what you would see from swallowing a pill. The time to reach peak blood levels was also much slower: around 8 hours for the gel versus about 1.5 hours for the oral dose. The overall bioavailability of the vaginal gel was about 56%, but because the applied dose is small, the total drug entering the bloodstream is still quite low.⁹

This matters because oral metronidazole carries a list of well-known side effects: nausea, a metallic taste, and a strict warning against alcohol (the combination can cause vomiting and flushing). The gel sidesteps most of those issues. You are not absorbing enough drug systemically for the metallic taste or the alcohol interaction to become practical concerns for most patients, though extremely cautious prescribers still mention it. For dermatological use on the face, systemic absorption is even lower than from vaginal application, making side effects beyond local skin irritation rare.

Side Effects of the Gel Itself

Topical metronidazole formulations used on the face are well tolerated. A review of rosacea trials found that stinging, dryness, burning, and itching were each reported in 2% of patients or fewer.¹⁰ That is a reassuringly low rate, especially for a medication people often apply daily for months or years.

Higher concentrations or different use contexts can push the numbers up. A study testing 2% metronidazole gel on acne found mild burning in about 31% and mild dryness in about 23% of treated areas, though none of these side effects were severe enough to make anyone quit the study.¹¹ The concentration you are prescribed and how sensitive your skin is will shape your experience, but across the board, the local side effects tend to be mild and manageable.

Controlling Odor From Fungating Wounds

An entirely different use for metronidazole gel is controlling the smell from fungating tumors, the open, often foul-smelling wounds that can develop in advanced cancer. The odor comes from anaerobic bacteria colonizing the wound, and metronidazole targets exactly those organisms. A phase 3 open-label study found that 0.75% metronidazole gel successfully deodorized the wound in about 95% of patients within two weeks.¹² The World Health Organization and the American Society of Clinical Oncology both recommend topical metronidazole for this purpose, favoring it over oral therapy because of its superior local efficacy.¹³

For patients and caregivers dealing with the distress of wound odor, this can be transformative. The smell from a fungating tumor is often the most socially isolating symptom of advanced disease, and a simple gel that resolves it within days can meaningfully improve quality of life even when the underlying cancer is beyond cure. Some patients do experience pain or burning when the gel is applied to open wound tissue, so careful technique and discussion with a palliative care team are important.

Perioral Dermatitis in Adults and Children

Perioral dermatitis, the bumpy, red rash that clusters around the mouth and sometimes the eyes, is another condition where metronidazole gel sees regular use. A multicenter trial comparing topical 1% metronidazole cream to oral tetracycline found both treatments effective, though oral tetracycline was significantly better. Metronidazole still reduced the median papule count to 8% of baseline after eight weeks, a meaningful improvement for a topical-only option.¹⁴ A review of the condition lists topical metronidazole among the treatment choices with good evidence.¹⁵

The gel is particularly useful for children, in whom oral antibiotics are less desirable. Case reports have documented significant improvement in pediatric perioral and periocular dermatitis after about two months of twice-daily 0.75% metronidazole gel, with complete clearing by 14 weeks.¹⁶ This condition in children is often triggered or worsened by topical corticosteroid use, and metronidazole gel offers a way to treat it without resorting to systemic antibiotics. A study of 24 Korean children with periorificial dermatitis found that the majority showed a complete response when treated with topical calcineurin inhibitors alongside topical or oral metronidazole.¹⁷ The condition also appears at all ages during childhood and adolescence, and topical metronidazole has been associated with clearing in published reports.¹⁸

Does the Gel Affect Your Skin’s Normal Bacteria?

A reasonable worry with any antibiotic, even a topical one, is whether it disrupts the normal microbial community of the skin. A study specifically investigating this found that topical metronidazole applied to the face for rosacea did not cause any significant changes in the skin or colon microflora.¹⁹ The drug’s selectivity for anaerobic organisms, combined with the low systemic absorption of topical application, appears to spare the broader microbial ecosystem. This is one of the advantages of topical delivery over oral metronidazole, which can disrupt gut flora and cause GI side effects.

Concentration, Dosing Frequency, and Formulation Choices

Metronidazole gel is available in 0.75% and 1% concentrations, and it also comes as a cream and a lotion. You might assume that the stronger concentration or more frequent application would work better, but the clinical data do not clearly support that assumption. A review of published trials found that confidence intervals for once-daily versus twice-daily dosing and for 0.75% versus 1% concentrations overlapped, meaning neither dosing frequency nor concentration showed a clear advantage over the other.²⁰ The practical upshot is that if once-daily application at 1% suits your routine, it is a reasonable choice, and if your insurance covers 0.75% twice daily instead, that works too.

The vehicle does matter for how the product feels on your skin. Gels tend to feel lighter and less greasy than creams, which some patients prefer under sunscreen or makeup. Creams may be more moisturizing for people with dry or sensitive skin. These cosmetic differences can influence whether someone keeps using the medication long term, which, for a chronic condition like rosacea, is arguably more important than small efficacy differences between formulations.

Pregnancy and Metronidazole Gel

Oral metronidazole has been widely studied in pregnancy, and the picture is mostly reassuring but not entirely clean. A review of the safety data found that metronidazole use did not predict birth defects or congenital abnormalities, but it was associated with an increased risk of spontaneous abortion, a finding the authors cautioned should be interpreted carefully because the underlying infections being treated are themselves risk factors for miscarriage.²¹ Most of that data concerns oral metronidazole, where systemic exposure is much higher. Topical and vaginal gel formulations deliver far less drug into the bloodstream, which in theory lowers any systemic risk. Still, many clinicians prefer to avoid prescribing metronidazole gel during the first trimester out of an abundance of caution, and you should discuss timing and alternatives with your provider if you are pregnant or planning to become pregnant.